{"date": "2022-02-08 16:11:55.190000+00:00", "ticker": "AMZN", "mrkt_info": {"open": 3158.71, "close": 3223.79}, "html": "<div class=\"storyContent\" lang=\"en\"><style type=\"text/css\">.storyContent * {border-color:inherit !important;outline-color:inherit !important;}</style><div class=\"tr-npp-body\">\n<pre>CELLEBRITE DI LTD (\"CLBT,CLBTW-Q\")\n- Deploys SaaS Investigative Digital Evidence Management Solution in\n- AWS London Data Center\n\n     Cellebrite, a global leader in Digital Intelligence (DI) solutions for\nthe public and private sectors, announced that Cellebrite Guardian\n(Guardian), a cloud-based investigative digital evidence management\nsolution designed specifically for investigators, examiners, and attorneys,\nis now available in the United Kingdom via Amazon Web Services (AWS).\nGuardian is part of Cellebrite's industry-leading DI Platform that offers\ncustomers an end-to-end investigative platform covering data collection,\nreview, analysis, and management, supporting the widest variety of digital\nevidence from the crime scene to the court.\n\n    In addition to the United States and United Kingdom, Cellebrite also\ndisclosed plans to deploy Guardian in AWS Data Centers in Canada,\nSingapore, and Australia before the end of 2022. The local data center\ndeployments, including today's roll out in the UK, are expected to better\nserve local law enforcement agencies and help them maintain data\nsovereignty in the region. By deploying Cellebrite Guardian to manage,\nstore, share, and review evidence, law enforcement agencies in the United\nKingdom are expected to process evidence four times faster than the present\nrate, according to Cellebrite's estimates.\n\n     Ronnen Armon, Chief Product and Technology Officer at Cellebrite,\ncommented: \"Through this expansion, Cellebrite is addressing the growing\nglobal demand for Investigative Digital Evidence Management Systems (IDEMS)\nthat allow law enforcement agencies to efficiently manage a rapidly\nincreasing volume of evidence within their investigations. We intend to\ncontinue to build our leading position in the IDEMS market by bringing our\ncloud-based solutions to data centers across the world in 2022.\"\n\n     For more information on Cellebrite Guardian, please visit here.\n\n     About Cellebrite\n\n  Cellebrite's mission is to enable its customers to protect and save lives,\naccelerate justice, and preserve privacy in communities around the world.\nWe are a global leader in Digital Intelligence solutions for the public and\nprivate sectors, empowering organizations in mastering the complexities of\nlegally sanctioned digital investigations by streamlining intelligence\nprocesses. Trusted by thousands of leading agencies and companies\nworldwide, Cellebrite's Digital Intelligence platform and solutions\ntransform how customers collect, review, analyze and manage data in legally\nsanctioned investigations.\n\nTo learn more visit us at www.cellebrite.com and\n<a href=\"https://investors.cellebrite.com\" data-type=\"url\" class=\"tr-link\" translate=\"no\">https://investors.cellebrite.com</a>.\n\n     Caution Regarding Forward Looking Statements\n\n     This document includes \"forward looking statements\" within the meaning\nof the \"safe harbor\" provisions of the United States Private Securities\nLitigation Reform Act of 1995. Forward-looking statements may be identified\nby the use of words such as \"forecast,\" \"intend,\" \"seek,\" \"target,\"\n\"anticipate,\" \"believe,\" \"could,\" \"continue,\" \"expect,\" \"estimate,\" \"may,\"\n\"plan,\" \"outlook,\" \"future\" and \"project\" and other similar expressions\nthat predict, project or indicate future events or trends or that are not\nstatements of historical matters. Such forward looking statements include\nestimated financial information. Such forward looking statements with\nrespect to revenues, earnings, performance, strategies, prospects, and\nother aspects of the business of Cellebrite are based on current\nexpectations that are subject to risks and uncertainties. A number of\nfactors could cause actual results or outcomes to differ materially from\nthose indicated by such forward looking statements. These factors include,\nbut are not limited to: Cellebrite's ability to develop technologically\nadvanced solutions and successfully integrate with the software solutions\nused by customers; acceptance of solutions by customers; errors, failures,\ndefects or bugs in solutions; a failure to maintain sales and marketing\npersonnel productivity or hire, integrate and retain additional sales and\nmarketing personnel; the impact of the global COVID-19 pandemic; the impact\nof competition on pricing and on Cellebrite's market share; sub-optimal\nresults from products due to misuse by customers; Cellebrite's failure to\nmaintain and enhance its reputation and brand; inaccuracy of the estimates\nof Cellebrite's market opportunity and forecasts of market growth; changes\nto packaging and licensing models that adversely affect the ability to\nattract or retain customers; failure to manage future growth effectively;\nfailure to introduce new solutions and add-ons; issues in the use of\nartificial intelligence resulting in reputational harm or liability; the\nneed for additional capital to support the growth of Cellebrite's business;\na failure to maintain the security of operations and the integrity of\nsoftware solutions; the impact of government budgeting cycles and\nappropriations, early termination, audits, investigations, sanctions and\npenalties; a decline in government budgets, changes in spending or\nbudgetary priorities, or delays in contract awards; a failure to adequately\nobtain, maintain, protect and enforce Cellebrite's intellectual property or\ninfringement of the intellectual property rights of others; perceptions or\ncourt or regulatory decisions that Cellebrite's solutions violate privacy\nrights; the use of solutions by customers in a way that is, or that is\nperceived to be, incompatible with human rights; failure to comply with\nlaws regarding privacy, data protection and security, technology\nprotection, sanctions, export controls and other matters; and other\nfactors, risks and uncertainties set forth in the sections titled \"Risk\nFactors\" and \"Cautionary Note Regarding Forward-Looking Statements\" in the\nfinal proxy statement/prospectus relating to Cellebrite's consummated\nbusiness combination filed with the SEC on August 5, 2021 and in other\ndocuments filed by Cellebrite with the SEC, which are available free of\ncharge at www.sec.gov. You are cautioned not to place undue reliance upon\nany forward-looking statements, which speak only as of the date made, in\nthis communication or elsewhere. Cellebrite undertakes no obligation to\nupdate its forward-looking statements, whether as a result of new\ninformation, future developments or otherwise, should circumstances change,\nexcept as otherwise required by securities and other applicable laws.\n\nMedia\nAdam Jaffe\nVP of Global Communications\n+1 973 206 7643\nadam.jaffe@cellebrite.com - or -\nRapidResponse@cellebrite.com\n\nInvestors\nAnat Earon-Heilborn\nVP Investor Relations\n+972 73 394 8440\ninvestors@cellebrite.com\n\nWWW   : <a href=\"https://www.cellebrite.com\" data-type=\"url\" class=\"tr-link\" translate=\"no\">https://www.cellebrite.com</a>    CELLEBRITE DI LTD\n                       ______________________________\n       _______________________________________________\n\n     ____________________________________________________________   \n      (c)2022 Market News Publishing Inc.  All rights reserved.    \n Toronto:(416)366-8881   Vancouver:(604)689-1101   Fax:(604)689-1106\n\n     2203800373.MNPRE2203802239-07562020220208</pre>\n</div><p class=\"line-break\"><br/></p><p class=\"tr-copyright\">Copyright (c) 2022 Thomson Reuters Limited.</p></div>"}